Tuberculosis

The Fine Art of Administering a Tuberculin Skin Test

By

Yeow Chye Ng, PhD, CRNP, CPC, AAHIVE

Louise C. O’Keefe, PhD, CRNP

Publish Date May 9, 2019

When administered correctly, the Mantoux test can be an invaluable tool for the detection of tuberculosis.

Whole Genome Sequencing Use in Predicting TB Resistance

By

Benjamin Patterson

Publish Date December 25, 2018

Whole genome sequencing of M tuberculosis isolates can identify complete drug susceptibility profiles, allowing precise treatment in early TB infection.

Could a New Universal Tuberculosis Regimen Help End the TB Pandemic?

By

Benjamin Patterson

Publish Date May 31, 2018

The Lancet Respiratory Medicine staged a debate between proponents and opponents of pan-TB regimens to tackle the current suboptimal worldwide management of TB resistance.

FDA: Tuberculosis Drugs May Contain Nitrosamine Impurities

By

Diana Ernst, RPh

Currently, there is no available evidence to assess the carcinogenic potential of MNP and CPNP.

Vitamin D Supplementation Does Not Lower Risk for Primary Tuberculosis Infection

By

Sweta Gupta

A team of investigators conducted a phase 3, double-blind trial to assess the impact of vitamin D supplementation on risk of tuberculosis infection in public schoolchildren in Mongolia.

Comparison Finds Rifampin Superior in Cost, Safety to Isoniazid for Latent Tuberculosis

By

Zahra Masoud

A shorter regimen of rifampin is safer and less expensive than the standard 9-month regimen of isoniazid for treatment latent tuberculosis.

Costs Associated With 4 Months of Rifampin vs 9 Months of Isoniazid in Latent TB

Health system use and costs higher for 9 months of isoniazid vs 4 months of rifampin in adults and children in all settings.

QuantiFERON-TB Gold Plus Comparable to Other Assays for Incident Tuberculosis

By

Bryant Moeller

QuantiFERON-TB Gold Plus was comparable to other interferon gamma release assays for predicting tuberculosis in adults with recent contacts.

Incidence of Tuberculosis High in Children Exposed to the Disease

Preventive therapy was effective in most children with tuberculosis if given before development of active disease.

Updated Guidelines for Latent TB Infection Treatment Released by CDC and NTCA

By

Brandon May

The National Tuberculosis Controllers Association and the Centers for Disease Control and Prevention have released updated guidelines for the treatment of latent tuberculosis infection.

Normal Dose Moxifloxacin Maintained Effectiveness in Rifampin-Resistant TB

By

Sheila Jacobs

A short, 9-month regimen of normal dose moxifloxacin maintained good effectiveness up to 24 months after therapy cessation in patients with rifampicin-resistant tuberculosis.